IMARC Group, a leading market research company, has recently releases report titled “Newborn Screening Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032” The global newborn screening market size reached US$ 1,026.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,777.7 Million by 2032, exhibiting a growth rate (CAGR) of 6.1% during 2024-2032.
Request For Sample Copy of Report For More Detailed Market insight: https://www.imarcgroup.com/newborn-screening-market/requestsample
Factors Affecting the Growth of the Newborn Screening Industry:
- Technological Innovations:
Advancements in mass spectrometry and genomic sequencing enable rapid, accurate, and cost-effective analysis of a wide array of genetic and metabolic disorders. Innovations in bioinformatics and the integration of artificial intelligence (AI) for data analysis further enhance the capability to interpret complex screening results. Enhanced precision and the ability to screen for multiple conditions improve early detection rates, leading to timely interventions. These technological innovations not only expand the spectrum of detectable conditions but also improve the reliability of screening outcomes.
- Favorable Government Initiatives:
Governing agencies of various countries are mandating screening programs to ensure that all newborns undergo screening for a variety of genetic, metabolic, endocrine, and functional disorders shortly after birth for early identification and intervention, which is impelling the market growth. They are providing funding for the infrastructure and resources needed to conduct these screenings, including advanced laboratories and trained personnel. Such policies assist in generating awareness among individuals about the importance of early disease detection and intervention for improved health outcomes and reduced morbidity and mortality among infants.
- Improving Healthcare Infrastructure:
The rising focus on newborn screening due to the improving healthcare infrastructure around the world is contributing to the market growth. Investments in healthcare facilities, laboratory capabilities, and trained personnel are essential for the implementation and scaling of newborn screening programs. Moreover, the enhancement of data management systems within healthcare infrastructure allows for the efficient handling of screening results, follow-up procedures, and patient records, ensuring that infants receive the necessary care without delay. Improved healthcare facilities benefit in reducing health disparities while improving public health outcomes.
Leading Companies Operating in the Global Newborn Screening Industry:
- Agilent Technologies Inc.
- Baebies Inc.
- Bio-RAD Laboratories Inc.
- Chromsystems Instruments & Chemicals GmbH
- Danaher Corporation
- Masimo Corporation
- Medtronic plc
- Natus Medical Incorporated
- Perkinelmer Inc.
- RECIPE Chemicals + Instruments GmbH
- Thermo Fisher Scientific Inc.
- Trivitron Healthcare
- Waters Corporation
Newborn Screening Market Report Segmentation:
By Product:
- Instruments
- Reagents
Instruments represent the largest segment as they are designed to ensure accuracy, efficiency, and reproducibility in the screening procedures.
By Technology:
- Tandem Mass Spectrometry
- Pulse Oximetry
- Enzyme Based Assay
- DNA Assay
- Electrophoresis
- Others
Tandem mass spectrometry holds the biggest market share on account of the rising need to identify a wide range of metabolic disorders.
By Test Type:
- Dry Blood Spot Test
- CCHD
- Hearing Screen
Dry blood spot test accounts for the largest market share, which can be attributed to its non-invasive nature.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America enjoys a leading position in the newborn screening market due to the increasing focus on preventive healthcare measures.
Global Newborn Screening Market Trends:
The escalating demand for newborn screening on account of the increasing incidence of congenital disorders and genetic diseases is supporting the market growth. Early diagnosis through screening can lead to timely interventions, thereby improving the prognosis for affected infants.
Apart from this, the growing awareness among healthcare providers and parents about the importance of early detection of congenital and hereditary conditions is offering a positive market outlook. There is a rise in the demand for comprehensive newborn screening among parents.
Other Key Points Covered in the Report:
- COVID-19 Impact
- Porters Five Forces Analysis
- Value Chain Analysis
- Strategic Recommendations
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
